IRB Barcelona is seeking a an outstanding and highly motivated postdoctoral researcher to join the Batlle Lab at IRB Barcelona for a unique translational research project at the interface of academia and industry. In close collaboration with the pharmaceutical industry, the successful candidate will investigate the activity of a novel therapy co-developed by the Batlle lab and the pharma in colorectal cancer (CRC).

This project offers the opportunity to work on a highly promising therapeutic program with genuine potential to impact patients. The successful candidate will use state-of- the-art models and approaches, including patient-derived organoids, in vivo models, and molecular and functional analyses.

If your dream is to contribute to discoveries that can directly benefit patients — or to build a career that bridges academic excellence and the biotechnology/pharmaceutical sectors — this project offers a rare chance to connect both worlds while working on an innovative therapy with clear momentum.

This project is co-funded by the: “Research Collaboration Agreement in Colorectal Cancer – MERUS” project.

YOU HAVE
- Applications are invited from highly motivated and ambitious researchers with a PhD degree and a strong track record in cancer biology, molecular biology, translational oncology, pharmacology, or related fields.
- Experience in organoid biology, therapeutic antibody research, drug response studies, colorectal cancer models, or in vivo work will be considered as an asset.
- Applicants should have excellent interpersonal and communication skills, strong organizational skills, and the ability to work both independently and as part of a team.

WHAT WE OFFER:
- A unique project in close collaboration with the pharmaceutical industry
- The opportunity to work on an innovative therapy with strong translational relevance
- Access to cutting-edge experimental models and technologies
- A stimulating, international, and highly collaborative research environment
- Direct exposure to both academic discovery and industry-driven drug development